COLUMBUS, Ohio — A new study by Ohio State University cancer researchers provides a rational for treating breast cancer by combining two kinds of targeted agents, one that inhibits an overactive, cancer-causing pathway in cancer cells and one that…
DURHAM, N.C. — Researchers at the Duke Cancer Institute who have been studying prostate cancer cells for decades now think they know why PSA (prostate-specific antigen) levels reflect cancer progression.
“This is the first demonstration of a me…
AURORA, Colo. (Dec. 22, 2010) — A class of drugs thought to kill cancer cells may in fact block “cross talk” between the cancer cell and normal immune cells, resulting in reduced cancer growth and spread — a discovery that could significantly alte…
A gene target for drug resistance, a triple-drug cocktail for triple negative breast cancer, and patients’ risk for carpal tunnel syndrome are among study highlights scheduled to be presented by Johns Hopkins Kimmel Cancer Center scientists during t…
Two thirds of breast cancers are ERalpha-positive, i.e., many estrogen receptors of the ERalpha- type are found in their cells. “These molecules can interact with the estrogen hormone and, thus, even lead to cancer,” explains Dr. Joerg Hoheisel; mol…
Scientists at Johns Hopkins have identified a compound that could be used to starve cancers of their sugar-based building blocks. The compound, called a glutaminase inhibitor, has been tested on laboratory-cultured, sugar-hungry brain cancer cel…
Cancerous and precancerous cells can detect that they are abnormal and kill themselves, or remain alive indefinitely but cease proliferating, through two intrinsic processes called programmed cell death and cellular senescence. One goal of cancer chemotherapy is to help stimulate these potent antitumor processes. Researchers at Cold Spring Harbor Laboratory on Long Island have recently shown that by locking cancer cells into a permanent state in which they remain alive but can no longer proliferate, cellular senescence contributes to successful outcomes following cancer therapy. Now, the same group has uncovered a precise molecular mechanism that helps trigger the “stop growing” response of cells. The study is published in the June 13 issue of the journal Cell.
By blocking a protein key to prostate cancer cell growth, researchers at the Lombardi Cancer Center at Georgetown University have discovered a way to trigger extensive prostate cancer cell death. This finding opens a new window for developing targeted treatments aimed at destroying prostate cancer cells before they have the opportunity to grow or spread. The study is published in the April 29 online issue of the Journal of Biological Chemistry.
Aspirin may reduce ovarian cancer growth, a laboratory study has shown. The study, published in the October issue of the journal Obstetrics and Gynecology, demonstrated that aspirin inhibited ovarian tumor cell growth by as much as 68 percent. The higher the dosage of aspirin added to the culture of ovarian cancer cells, the more growth inhibition was observed.